December 18, 2015

AstraZeneca on Thursday announced that it has agreed to acquire a majority stake in privately-held, cancer-drug developer Acerta Pharma for $4 billion. (New York Times)

December 17, 2015

The Rare Disease COE is custom-built to serve the unique needs of rare-disease populations, with a team of specialists who establish one-on-one relationships with patients.

December 16, 2015

CVS Health shared five key innovations that are delivering value both to patients and strategic partners in growing its retail pharmacy business at its annual analyst day. 

December 15, 2015

The Food and Drug Administration has approved Teva and Eagle Pharmaceuticals’  Bendeka (bendamustine hydrochloride), an injection and 10-minute infusion formulation. 

December 15, 2015

Significantly, 53% of employers have added new coverage and utilization restrictions for specialty pharmacy, such as requiring prior authorization or limiting quantities based on clinical evidence.

December 15, 2015

The Food and Drug Administration approved the new multiple myeloma drug four months ahead of the date of its Priority Review. 

December 4, 2015

According to the report, from 2009 to 2014, branded and generic specialty sales in the United States grew at an annual compound growth rate of 12%, with a dominant force being oncology. 

December 2, 2015

According to an Associated Press report published in the New York Times, a bipartisan Senate Finance committee report found that Gilead Sciences, maker of hepatitis C treatments Harvoni and Sovaldi, chose to price Sovaldi at $1,000 a pill ($84,000 for a course of treatment) despite evidence that a lower price would allow more people to take advantage of the treatment. Gilead rejected the committee’s conclusions, noting that it “responsibly and thoughtfully priced Sovaldi and Harvoni,” as lawmakers point to this case as a cautionary tale for other expensive treatments. (New York Times)

December 2, 2015

The Detroit Free Press Top Workplaces are based solely on employee feedback. In Michigan this year, more than 61,000 employees filled out surveys.  

November 30, 2015

Takeda’s Ninlaro is a treatment for patients with multiple myeloma who have had at least one prior therapy. 

November 30, 2015

The combined company’s revenue for the 12 months ended June 30 exceeded $800 million. 

November 24, 2015

Eli Lilly and Co.’s Petrazza in a trial extended the lives of patients who took the drug in combination with two forms of chemotherapy to 11.5 months. 

November 20, 2015

The average annual cost of a specialty medication used on a chronic basis exceeded $53,000 in 2013, which is more than the median U.S. household income, AARP noted. 

November 20, 2015

Specialty medications represent only 1% of all prescriptions but, in 2014, these medications resulted in over 31% of all drug spending.

November 19, 2015

The healthcare logistics industry has seen significant improvements in product security and regulatory compliance across the supply chain. 

November 18, 2015

AxelaCare enhances OptumRx’s ability to deliver care to the growing number of consumers managing complex conditions through at-home infusions.

November 17, 2015

Tagrisso is an EGFR-tyrosine kinase inhibitor, a targeted cancer therapy, designed to inhibit both the activating, sensitizing mutations, and T790M, the genetic mutation responsible for EGFR-TKI treatment resistance in up to approximately two-thirds of cases of EGFRm advanced NSCLC. 

November 13, 2015
The drug was granted Fast Track, Breakthrough, Priority Review and Accelerated Approval status by the FDA and has shown an objective response rate of 59% with a median duration of about 12.4 months. 
November 12, 2015

The moves are part of a strategic move to align efforts for internal improvement, the specialty pharmacy operator said. 

November 11, 2015

The combination of Cotellic with Zelboraf helps patients with previously untreated BRAF V600 mutation-positive advanced melanoma live a median of one year (12.3 months) without their disease worsening, compared to 7.2 months with Zelboraf alone.

November 11, 2015

A new drug has been approved that, in conjunction with vemurafenib, is meant to treat metastatic melanoma that can't be removed through surgery with a certain gene mutation. 

November 11, 2015

Consider this: 1-in-5 hospital patients end up back in the hospital within 30 days of their discharge. And the biggest factors pulling them back all have to do with medications — either through medication errors, nonadherence or adverse drug events.

November 6, 2015

Novira is a company working on curative treatments for chronic hepatitis B.